Roche Holding AG's (Basel CHE) new drug for advanced melanoma, Zelboraf, on average helped patients with the deadly disease live for more than a year, according to data from a late-stage trial

May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article informs that data from a late-stage trial found that Roche Holding AG's new drug for advanced melanoma, Zelboraf, help patients with the deadly disease to live for more than a year. It has been informed that the trial is a follow-up to a pivotal 675-patient Phase III study which was presented at the American Society of Clinical Oncology meeting and led to the drug's approval.


Related Articles

  • FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation- Positive Metastatic Melanoma, a Deadly Form of Skin Cancer.  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p270 

    The article focuses on the approval by the U.S. Food and Drug Administration for the Zelboraf (Vemurafenib) drug from Genentech Inc. to treat BRAF Mutation-Positive Metastatic Melanoma, a form of skin cancer. It says that the drug approval is based on the results of BRIM3 and BRIM2 clinical...

  • T-DM1 Slows Breast Cancer, With Fewer Side Effects. Breindl, Anette // BioWorld International;6/6/2012, Vol. 17 Issue 23, p4 

    The article offers information on data from the Phase III Emilia trial of antibody-drug conjugate T-DM1 by Roche AG subsidiary Genentech Inc. and partner ImmunoGen Inc. The data was presented at the 2012 American Society of Clinical Oncology (ASCO) annual meeting. They showed that treatment with...

  • European Oncology Conference.  // BioWorld Today;9/24/2009, Vol. 20 Issue 184, p3 

    The article discusses data from a Phase I extension study of PLX 4032 in metastatic melanoma patients, presented by Plexxikon Inc. at the European Oncology Conference held in Berlin, Germany. Based on trial results, Almost all evaluable patient presented tumor shrinkage. The company developed...

  • Roche: Avastin continues to march on.  // PharmaWatch: Cancer;Aug2006, Vol. 5 Issue 8, p15 

    The article reports that Roche Pharmaceuticals has submitted a marketing authorization application to the European Medicines for Avastin in previously untreated advanced breast cancer. The European filing of Avastin for the first-line treatment of advanced breast cancer was based on results of...

  • New drugs for metastatic melanoma offer hope to patients. Droppert, Pieter // Pharmacy Today;Aug2011, Vol. 17 Issue 8, p44 

    The article presents new data for the treatment of metastatic melanoma which were highlight in the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. One of these drugs is the vemurafenib from F. Hoffman-La Roche Ltd./Genentech Inc. which was shown to...

  • Cancer findings at ASCO.  // European Pharmaceutical Executive;Jul/Aug2005, p10 

    The article highlights the 41st annual meeting of the American Society of Clinical Oncology, held in May 2005 in Orlando, Florida. the event was participated by almost 25,000 doctors, nurses, patients and employees of pharmaceutical companies. Among the many companies who reported on recent...

  • How Melanoma Gets Around PLX4032: Counting The Ways. Breindl, Anette // BioWorld Today;11/29/2010, Vol. 21 Issue 229, p1 

    The article reports that majority of patients with melanoma have developed resistance to the drug PLX4032 from Plexxikon Inc. and Roche AG in less than a year since starting treatment. A Phase I trial of the drug in early 2010 demonstrated a response rate of more than 80 percent. According to...

  • PLX4032 Shines in Phase II; Possible Early Approval? Boggs, Jennifer // BioWorld Today;11/8/2010, Vol. 21 Issue 216, p1 

    The article reports on the results of an open-label Phase II trial for Plexxicon Inc. and Roche AG's melanoma drug PLX4032. A 52 percent response rate was observed in patients with previously treated disease with the BRAF V600E mutation. According to Gideon Bollag, senior vice president of...

  • Plexxikon Drug Quickly Moves From Phase I to Pivotal Trials. Hollingsworth, Catherine // BioWorld Today;9/30/2009, Vol. 20 Issue 188, p1 

    The article reports that PLX4032, the melanoma drug from Plexxikon Inc. has moved from a Phase I study to pivotal trials. The move has prompted F. Hoffmann-La Roche Ltd., Plexxikon's co-developer for the product, to provide an undisclosed milestone payment under a 2006 agreement. It describes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics